Table 4.
Demographic characteristics of 2280 TApHOD patients at the time of first clinic visita
| Demography | Retained in the programme (n = 1731) | Lost to follow-up (n = 549)b | P-valuec |
|---|---|---|---|
| Age (years) | 0.197 | ||
| <1 | 252 (14.6) | 78 (14.2) | |
| 1–4 | 505 (29.2) | 184 (33.5) | |
| 5–9 | 663 (38.3) | 208 (37.9) | |
| 10–14 | 296 (17.1) | 74 (13.5) | |
| ≥15 | 15 (0.9) | 5 (0.9) | |
| Median age, years (IQR) | 5.8 (2.4–8.9) | 5.3 (2.2–8.3) | |
| Sex | 0.197 | ||
| Female | 865 (50.0) | 257 (46.8) | |
| Male | 866 (50.0) | 292 (53.2) | |
| Ethnicity | <0.0001 | ||
| Thai | 1123 (64.9) | 283 (51.6) | |
| Indian | 197 (11.4) | 203 (37.0) | |
| Indonesian | 132 (7.6) | 16 (2.9) | |
| Malay | 115 (6.6) | 12 (2.2) | |
| Khmer | 86 (5.0) | 15 (2.7) | |
| Chinese | 22 (1.3) | 3 (0.6) | |
| Other/unknown | 56 (3.2) | 17 (3.1) | |
| Mode of exposure | 0.047 | ||
| Perinatal | 1628 (94.1) | 470 (85.6) | |
| Blood products | 19 (1.1) | 15 (2.7) | |
| Sexual intercourse/ abuse | 9 (0.5) | 2 (0.4) | |
| Other/unknown | 75 (4.3) | 62 (11.3) | |
| Infant ARV exposure | 0.004 | ||
| Yes | 184 (10.6) | 31 (5.7) | |
| No | 968 (55.9) | 86 (15.7) | |
| Unknown | 579 (33.5) | 432 (78.7) | |
| Maternal ARV exposure | 0.015 | ||
| Yes | 156 (9.0) | 26 (4.7) | |
| No | 1000 (57.8) | 94 (17.1) | |
| Unknown | 575 (33.2) | 429 (78.1) | |
| CD4+cell percent | 0.449 | ||
| <10 | 429 (24.8) | 125 (22.8) | |
| 10–14 | 130 (7.5) | 33 (6.0) | |
| 15–24 | 208 (12.0) | 75 (13.7) | |
| ≥25 | 130 (7.5) | 39 (7.1) | |
| Unknown | 834 (48.2) | 277 (50.5) | |
| Median %CD + (IQR) | 10.0 (3.0–20.0) | 11 (4.0–19.9) | |
| WHO clinical stagingd | 0.008 | ||
| Stage I/II | 357 (20.6) | 87 (15.8) | |
| Stage III | 326 (18.8) | 152 (27.7) | |
| Stage IV | 262 (15.1) | 57 (10.4) | |
| Unknown | 786 (45.4) | 253 (46.1) | |
| Severe anaemiae | 0.641 | ||
| Yes | 61 (3.5) | 19 (3.5) | |
| No | 951 (54.9) | 261 (47.5) | |
| Unknown | 719 (41.5) | 269 (49.0) | |
| Mean haemoglobin, Hb (SD) | 10.4 (1.9) | 10.5 (1.9) | |
| ARTf | <0.0001 | ||
| Mono or dual therapy | 182 (10.5) | 90 (16.4) | |
| HAART-NNRTI | 1219 (70.4) | 163 (29.7) | |
| HAART-NNRTI\PI | 7 (0.4) | 0 | |
| HAART-NRTI | 3 (0.2) | 1 (0.2) | |
| HAART-PI | 67 (3.9) | 20 (3.6) | |
| No ART | 253 (14.6) | 275 (50.1) | |
| Prophylactic treatments | <0.0001 | ||
| Yes | 709 (41.0) | 290 (52.8) | |
| No | 1022 (59.0) | 259 (47.2) | |
Values are numbers (percentages) unless stated otherwise.
Percentages may not add up to 100% due to rounding.
aFor CD4+ the closest value within the 3 months before the date of enrolment is used. For haemoglobin and prophylactic treatment the closest value within the 3 months before and one month after enrolment in the clinic are used.
bIncludes those who have been transferred to other clinics or temporary involved in another study.
cExcluding the unknown categories.
dMaximum stage before enrolment is used.
eSevere anaemia was defined according to US guidelines: Hb <10 g/dL for children <21 days; Hb < 8 g/dL for children between 22 and 35 days; Hb < 7 g/dL for children between 36 and 56 days; Hb < 7.5 g/dL for children ≥57 days.
fRefers to the first ART regimen.
SD: standard deviation.